Solasia Pharma K.K.

Equities

4597

JP3436500007

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-03-29 am EDT 5-day change 1st Jan Change
33 JPY +3.12% Intraday chart for Solasia Pharma K.K. -2.94% -26.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond CI
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited CI
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains MT
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index CI
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe MT
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program CI
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study MT
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 CI
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation. CI
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 CI
Solasia Announces Summary of SP-04 PledOx Development Status CI
Solasia Launches Anticancer Injection Darvias MT
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 CI
Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin) CI
Solasia Pharma K.K. announced that it has received Ñ1.02 billion in funding from Nippon Kayaku Co., Ltd. CI
Solasia Takes Over Episil Oral Liquid Business from Camurus MT
Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (OM : CAMX). CI
Solasia Pharma to Divest Sales Function for Two Chemotherapy-support Drugs to Lee's Pharmaceutical MT
Chart Solasia Pharma K.K.
More charts
Solasia Pharma K.K. is a Japan-based pharmaceutical company. The Company is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. It focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The Company's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
32 JPY
Average target price
100 JPY
Spread / Average Target
+212.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Solasia Pharma K.K. - Japan Exchange
  4. News Solasia Pharma K.K.
  5. Solasia Pharma Partner Receives Fast Track Designation from US FDA for Cancer Drug Development